-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $43

Benzinga·11/18/2025 14:51:25
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and raises the price target from $28 to $43.